KING PHARMACEUTICALS INC
- Alvogen to Acquire Product Portfolio from Pfizer for the U.S. Market Business Wire Health News
- Pfizer Receives Approval from the Australian Competition and Consumer Commission for Pending Acquisi BusinessWire Science News
- Pfizer wins EU approval for $15 billion Hospira buy Fidelity - Merger and Acquision News
- Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Mu Business Wire Health News
- $400M Pfizer Class Action Deal Gets OK From Judge Law 360 Securities
- Pfizer expands Cambridge Kendall Square research facility Clinical Trials Today [CenterWatch]
- Pfizer Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline Business Wire Health News
- U.S. jury clears Pfizer in second trial over Zoloft Reuters - Sectors - Healthcare
- Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company Business Wire Health News
- Pfizer Pays $87.5 Million Upfront for Stake in AM-Pharma Holding BV With Option to Swallow Entire Co Bio Space - All News
Community Payment Ratings
Cortera is much more than an awesome business directory! It's an active community where real business people share the real deal on real businesses.
It's invaluable intel that's now available for FREE.
- Get the inside scoop with ratings and reviews on KING PHARMACEUTICALS INC
- Rate KING PHARMACEUTICALS INC on their payment behavior
- Ask your network about KING PHARMACEUTICALS INC with Cortera Circles
The information contained in this company profile is compiled from third party sources, including but not limited to public records, user submissions, and other commercially available data sources. These sources may not be accurate, complete, or up-to-date. Cortera makes no representations or warranties regarding, and assumes no responsibility for, the accuracy, completeness, or currency of the information contained herein.